Search results
4 days ago · Company emerges with an initial commitment of $50 million from Flagship Pioneering. CAMBRIDGE, Mass., September 26, 2024 – Flagship Pioneering, the bioplatform innovation company, today unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic ...
4 days ago · Mirai's machine intelligence-based, open platform unlocks delivery to any tissue and cell type through rapid, iterative learning of in vivo tested chemistries. Co-optimization of cargo design and ...
4 days ago · Mirai, whose founding CEO is Geoffrey von Maltzahn, PhD, features an open end-to-end platform to enable the co-creation of fully optimized genetic medicines, according to Hari Pujar, PhD, founding ...
4 days ago · Mirai Bio. Mirai Bio has built an open platform driven by machine intelligence that solves the key limitations hindering today’s genetic medicines – delivery, design, and manufacturing.
4 days ago · Flagship hopes biotechs will flock to Mirai’s algorithm-based platform to enhance their genetic meds. Amid the genetic medicines arms race, Flagship Pioneering is unveiling a new company to help ...
4 days ago · Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best way to get their drugs to patients. The new Cambridge, Massachusetts-based company ...
3 days ago · Pharmaceutical. Headquarters Regions Greater Boston Area, East Coast, New England. Founded Date 2021. Operating Status Active. Last Funding Type Series A. Company Type For Profit. Mirai Bio has developed an open platform powered by AI to address the main drawbacks and manufacturing to develop the future of genetic medicine.
